Table 5.
Correlation analyses of changes in serum THBS1 and metabolic parameters during weight reduction therapy.
Variable | Male n = 34 |
Female n = 44 |
Premenopausal n = 20 |
Postmenopausal n = 24 |
||||
---|---|---|---|---|---|---|---|---|
γs | P | γs | P | γs | P | γs | P | |
ΔBMI | −0.16 | 0.357 | 0.09 | 0.543 | 0.47 | 0.035* | −0.15 | 0.493 |
ΔWC | 0.09 | 0.631 | −0.01 | 0.970 | 0.25 | 0.283 | −0.28 | 0.186 |
ΔVAT area | −0.03 | 0.875 | 0.13 | 0.433 | 0.38 | 0.135 | −0.15 | 0.516 |
ΔSAT area | −0.02 | 0.910 | 0.02 | 0.895 | 0.13 | 0.633 | 0.01 | 0.970 |
ΔFPG | −0.16 | 0.355 | 0.00 | 0.978 | 0.30 | 0.204 | −0.28 | 0.189 |
ΔHbA1c | −0.17 | 0.323 | −0.06 | 0.703 | 0.32 | 0.175 | −0.41 | 0.044* |
ΔIRI | −0.08 | 0.689 | −0.07 | 0.672 | 0.16 | 0.535 | −0.20 | 0.365 |
ΔHOMA-IR | −0.10 | 0.600 | −0.05 | 0.759 | 0.22 | 0.400 | −0.25 | 0.260 |
ΔTG | −0.28 | 0.112 | −0.11 | 0.486 | 0.06 | 0.806 | −0.28 | 0.182 |
ΔHDL-C | −0.09 | 0.597 | 0.12 | 0.435 | 0.08 | 0.728 | 0.08 | 0.714 |
ΔLDL-C | 0.07 | 0.712 | −0.21 | 0.170 | 0.18 | 0.440 | −0.58 | 0.003* |
ΔAST | 0.15 | 0.387 | −0.15 | 0.347 | 0.02 | 0.947 | −0.29 | 0.172 |
ΔALT | 0.17 | 0.331 | 0.03 | 0.865 | 0.17 | 0.474 | −0.11 | 0.619 |
ΔγGTP | −0.06 | 0.748 | −0.20 | 0.215 | −0.10 | 0.736 | −0.23 | 0.284 |
ΔLeptin | −0.20 | 0.270 | −0.10 | 0.530 | 0.11 | 0.658 | −0.18 | 0.406 |
ΔAdiponectin | 0.30 | 0.097 | 0.06 | 0.700 | 0.06 | 0.819 | 0.07 | 0.764 |
ΔhsCRP | −0.25 | 0.175 | −0.04 | 0.795 | −0.01 | 0.977 | −0.04 | 0.861 |
The parameter change (Δ) was defined as the level after 6 months minus the level at the baseline. Spearman’s rank correlation coefficient (γs) was used to assess the relationships among the study variables.
P < 0.05.